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S_inmary Laser-induced fluorescence (LIF) was used to characterise the localisation of an intravenously
administered trimethylated carotenoporphyrin [CP(Me)3] and a trimethoxylated carotenoporphyrin
[CP(OMe)3] in an intramuscularly transplanted malignant tumour (MS-2 fibrosarcoma) and healthy muscle in
female Balb/c mice, 3, 24, 48 and 96 h post injection. The fluorescence was induced with a dye laser pumped
by a nitrogen laser, emitting light at 425 rm. The fluorescence spectra were recorded in the region 455 -760 nm
using a polychromator equipped with an image-intensified CCD camera. The tumour/peritumoral muscle ratio
was about 5:1 for CP(Me)3 and about 6:1 for CP(OMe), in terms of the background-free fluorescence
intensity, which peaked at about 655 nm. By including the endogenous tissue fluorescence, the contrast was
further enhanced by a factor of approximately 2.
In some clinical situations, tumour diagnostic techniques may
fail to localise precancerous lesions and superficial tumours,
e.g. in the tracheobronchial area, the oesophagus, the urinary
bladder and the ear/nose throat region. Biopsy sampling is
often performed in a blind way during conventional tumour
screening procedures; hence, the malignant areas may not be
localised. Therefore, there is a need to develop more sensitive
methods. Laser-induced fluorescence (LIF) in conjunction
with different photosensitisers is a new, rapidly evolving
modality which has exhibited promising results in early
tumour localisation (Cortese et al., 1979; Doiron et al., 1979).
Most frequently, various derivatives of porphyrins, such as
haematoporphyrin derivative (HpD) (commercial name
Photofrin), have been used. These substances give rise to a
characteristic red fluorescence when excited in the UV or
near-UV region. As accumulation of the photosensitising
substance occurs in premalignant and malignant areas,
diseased tissue is characterised by a higher fluorescence inten-
sity in the red wavelength region, compared with most non-
diseased tissues. For example, LIF of tumours in the
bronchial tree and the urinary bladder in conjunction with
low-dose HpD in clinical diagnostics has been performed
(Lam et al., 1990; Baert et al., 1992). Premalignant and in
situ malignant lesions were localised.
Although HpD has tumour-localising properties with a
discnrmination towards normal tissue of about 2-3:1 for
various malignant lesions, several factors limit its widespread
use as a photodiagnostic agent, including the heterogeneous
chemical composition and the presence of non-fluorescent
aggregated material, the limited selectivity and the prolonged
persistence of general cutaneous photosensitivity if
administered in therapeutic doses (Dougherty, 1987; Razum
et al., 1987). The development of new sensitisers has mainly
emphasised their therapeutic effects, including high single
oxygen yield for the induction of tumour necrosis and light
absorption at wavelengths close to 700nm for deep light
penetration. Also, less skin photosensitisation, as compared
with HpD, is a major goal. Substances which have been
studied include phthalocyanines (Pcs) (Spikes, 1986), various
derivatives of cholorphyll, chlorins (Nelson et al., 1987),
purpurins (Kessel, 1989) and some additional porphyrin
derivatives. Lately, 6-aminolaevulinc acid (ALA) (Kennedy et
al.. 1990: Kennedy & Pottier, 1992; Grant et al.. 1993;
Svanberg et al.. 1994), a precursor to haem, and benzopor-
phyrin derivative (BPD) (Richter et al., 1987, 1988, 1990)
have been investigated. MACE (mono-aspartyl chlorin ed)
does not induce any cutaneous photosensitivity at all,
because of a fast clearance rate (Nelson et al.. 1987).
Recently, a new class of tumour-localising substances has
been developed solely for tumour demarcation capability,
without any photosensitising effect. These substances consist
of carotenoid polyenes covalently linked to porphyrins, in
which the tetraaryl porphyrin moiety carries either three
methyl (Me) or three methoxy (OMe) groups (Reddi et al.,
1994). These carotenoporphyrins (CPs) have the unique
capability of mimicking carotenoid photoprotection such as
occurs in the photosynthetic reaction centres of green plants.
The carotene moiety rapidly quenches the porphyrin triplet
state, thus preventing the porphyrin-sensitised formation of
cytotoxic 102 (Gust et al., 1992a). Accordingly, CPs cannot
be used for photodynamic therapy (PDT), but are valuable
alternatives for LIF-mediated detection of malignant lesions,
because they are designed to reduce damage to skin and
other organs.
In this paper, we report on laser-induced fluorescence
measurements in mice injected with CP(Me)3 or CP(OMe)3.
The acquired spectra were used to characterise a transplanted
fibrosarcoma and normal muscle (peritumoral tissue), follow-
ing excitation at 425 nm. Similar studies have been carried
out previously using other substances such as HpD
(Svanberg et al., 1986), haematoporphyrin (Hp) (Andersson-
Engels et al., 1989a), polyhaematoporphyrin ester (PHE)
(Andersson-Engels et al., 1989a), tetrasulphonated Pc (TSPc)
(Andersson-Engels et al., 1989a) and BPD-monoacid
(BPD-MA) (Andersson-Engels et al., 1993), in other experi-
mental tumour systems.
In addition to simply using the substance-related
fluorescence, the endogenous fluorescence emanating from
natural fluorophores in the tissue may also be included in
order to enhance the tumour demarcation towards healthy
peritumoral tissue. It has been shown that the autofluor-
escence, with its intensity maximum at about 500 nm when
excited in the near-UV region, shows a lower intensity in
tumour than in normal tissue (Ankerst et al., 1984; Profio &
Sarnaik, 1984; Lohmann et al., 1989; Andersson-Engels et
al., 1989b, 1991a; Cothren et al., 1990; Hung et al., 1991;
Baert et al., 1992). To some extent, the reason for the
decreased autofluorescence seems to be a decrease in the
amount of oxidised forms of flavins in malignant tissue
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(Hung et al., 1991). Another reason for the decrease in
tumour autofluorescence might be a change in the relative
amounts of the highly fluorescent reduced form of
nicotinamide adenine dinucleotide (NADH) and the weakly
fluorescent oxidised form NAD+ in malignant tumours
(Svanberg et al., 1986; Lohmann & Hugo, 1989; Andersson-
Engels et al., 1991b). Tumour-induced transformation of the
tissue collagen, which normally exhibits a high fluorescence
intensity at about 390 nm, may also be important. When
tumour cells invade a host tissue, tumour-specific collagenase
type IV is released (Poulsom et al., 1992; Campo et al.,
1992), which may destroy the healthy collagen with loss of
the high, collagen-specific fluorescence intensity.
Results from in vivo clinical tumour investigations with UV
and near-UV excitation clearly show a decrease in the
autofluorescence signal in the tumour compared with the
peritumoral tissue (Hung et al., 1991; Baert et al., 1992). By
measuring the ratio between the exogenous fluorescence,
which increases in tumour, and the autofluorescence, which
decreases, the tumour/peritumoral tissue demarcation is
enhanced. In addition, the designation of a dimensionless
ratio also implies an insensitivity to fluctuations in excitation
and detection equipment and variations in surface topo-
graphy or differences in the distance between the optical fibre
and the tissue being analysed.
Material nd mthods
Chemicals
The carotenoporphyrins were synthesised at Arizona State
University according to the procedures previously described
(Gust et al., 1992b). Their structural formulas are shown in
Reddi et al. (1994). A 5 mg aliquot ofcarotenoporphyrin was
added to 0.5 ml of Cremophor and sonicated until the CP
was completely dispersed in the emulsifier agent. The suspen-
sion was added to 0.15 ml of absolute ethanol, sonicated
again and taken to a final volume of lOml by the stepwise
addition of a saline solution at pH 7.4. The final Cremophor
emulsion was filtered through a 0.45pm filter and the CP
concentration (0.45-0.5 mg) was determined spectrophoto-
metrically after a 1:200 dilution of a small aliquot of emul-
sion in absolute ethanol and using an extinction coefficient of
3.74 x 105 mmol ' cm-' at 420 nm. The CPs in the Cremo-
phor emulsion were i.v. injected to tumour-bearing mice at a
dose of 4.2p.mol kg-1 [5.0 and 5.2 mg kg-' of CP(Me)3 and
CP(OMe) respectively]. Cremophor EL was supplied by
Sigma. All other chemicals and solvents were analytical-grade
reagents.
Anbnals and tumour
Female Balb/c mice (18-22 g body weight) received 0.2 ml of
a cell suspension containing 106 MS-2 fibrosarcoma cells
ml-'. The tumour grows intramuscularly in the right hind leg
6 days before the first day of measurement (Reddi et al.,
1994).
In vivo andex vivofluorescence measurements
Figure 2 illustrates the method used for the fluorescence
measurements. A scan over healthy muscle and tumour tissue
was performed, and also, in the ex vivo situation, a reference
measurement in the non-diseased left hind legs of the mice
was taken. The in vivo scans were performed after an i.p.
injection ofapproximately 0.09 ml Ketalar (50 mgml-') from
Parke Davis, Milan. After the animal was anaesthetised, the
skin over the tumour and surrounding mucscle was cut open,
the scan was performed and the animal was sacrificed with
ether. In the dead mice, the optical fibre was inserted a few
millimetres into the tissue, where fluorescence measurements
were carried out.
Two points were measured at 5 and 2 mm outside the
tumour in healthy muscle. Inside the tumour, five points were
chosen for measurements, the first and last point being about
I mm from the tumour border with healthy muscle, and the
other points being equally spaced along a line bisecting the
tumour. The diameters of the tumours were about 15 mm at
the time of analysis. The tumour model used (fibrosarcoma
MS-2) was not optimal in that necrotic areas appeared rather
quickly. No major necrosis was present in the measurements
3 and 24 h post injection, and the few points where recor-
dings had been taken from necrotic areas were deleted before
the data analysis was performed. In the case of the 48 h
measurements, the amount of necrosis had increased some-
what, but the same procedure was followed. For the 96 h
groups, no points whatsoever were deleted, which is reflected
in the great standard deviations of the fluorescence signal.
This is especially true for the substance CP(Me), which, at
96 h, exhibited huge standard deviations as a consequence of
very necrotic tumours. The necrosis also predisposed to
haemorrhages, which further interfered with the fluorescence
because of light reabsorption by blood in the green-yellow
spectral region.
Equipment
The optical set-up used for the recordings of laser-induced
fluorescence is similar to one previously described
(Andersson-Engels et al., 1989a, 1991a) and will only be
briefly described here. The excitation source was a nitrogen
laser (Laser Science VSL-337ND) used alone or as pump
source for a compact dye laser (Laser Science DLM220). The
output pulse energy of the nitrogen laser was 180iJ, the
pulse duration 3 ns and the repetition rate about 10 Hz. For
the dye laser the output energy was up to 20pU and the
wavelength could be varied by turning a grating. For these
measurements, the wavelength was set at 425 nm. The laser
light was focused onto the tip of a fluorescence-free 600 im
optical fibre and the distal end of the fibre was held in
contact with the animal tissue. The fluorescence guided back
through the same fibre was transmitted through a dichroic
mirror, which at the same time blocks out the reflected
excitation light, and focused at the 100#m entrance slit of a
polychromator (Acton SP-275). A cut-offfilter at 455 nm was
used to remove any residual elastically scattered excitation
light. The detector was a 576 x 384 pixel image-intensified
charge-coupled device (CCD) camera (Spectroscopy Instr.
ICCD-576G/R) cooled to -20C. In total, about 2,500
fluorescence spectra were recorded and stored on floppy discs
for evaluation. The fluorescence from 50 laser pulses was
integrated for each spectrum, although in most cases useful
signal-to-noise was obtained in single shot.
Results and DEscassio.
Figure I shows six fluorescence spectra recorded in vivo from
the exterior part of the tumours and from healthy muscle
fasciae, surrounding the malignant tumours, in two animals
injected 3 h earlier with (a) CP(Me) and (b) CP(OMe), and
(c) in a non-injected control animal. The heavy line denotes
malignant tissue and the thin one healthy muscle.
The carotenoporphyrin-specific fluorescence is character-
ised by two peaks. In the case of CP(Me)3 the peaks are at
654 and 720 nm, whereas they are slightly shifted to the red
in the case of CP(OMe)3, appearing at 658 and 722 nm. The
fluorescence intensities at the peaks were evaluated with the
background fluorescence subtracted, as marked in the Figure.
The first substance-specific free-standing peak is denoted 'A'
and the endogenous fluorescence 'B'. The ratio between A
and the second substance-related peak varied slightly accord-
ing to substance injected and time elapsed since injection.
The variations, however, were insignificant and the ratios
were about 2.1 for CP(Me)3 and 2.3 for CP(OMe)3. The
values did not differ significantly between tumour and nor-
mal muscle. The tissue autofluorescence has its maximum at
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Figwe I In vivo spectra taken 3 hi post i.v. injection of
4.2pmol kg-' of a, CP(Me)3 and b, CP(OMe)3. Below, inc, two
spectra are shown from a non-injected control animal. These in
vivo measurements were carried out as exterior scans over heal-
thy, peritumoral muscle fascia and tumour capsule, with the skin
remnoved. The thin line represents a location outside the tumour,
on healthy muscle fascia, and the heavy line represents a location
inside the tumour. 'A', at the top of the figure, denotes the
background-free peak, located at 654 am in the cas of CP(Me)3,
and 'B' represents the autofluorescence, evaluated at 490 nm.
evaluated at 490 num (B) a wavelength frequently used for
monitoring endogenous fluorescence.
The spectra from the injected animals show, when com-
pared with those from the control animal, that the caro-
tenoporphyrins are retained with good selectivity in tumour
tissue, as compared with surrounding muscle, in the in vivo
situation. We found that on average for all groups of mice
CP(Me)3 showed about five times higher fluorescence in
tumour than in muscle, and that the corresponding value was
about 6 for CP(OMe)3, according to measurements based on
the substance-related peak A. The autofluorescence in the
blue-green wavelength region (B) has a lower intensity in
tumour tissue than in the surrounding muscle, although the
excitation wavelength used (425 nm) is not the optimal one
for exciting NADH and collagen.
Figure 2 shows a typical fluorescence scan, recorded ex
vivo, with the fibre inserted into the tissue in an animal
injected with (a) CP(Me)3 or (b) CP(OMe)3 3 h earlier. The
dual-peaked substance-related fluorescence is clearly seen in
the points recorded from the tumour, including the border
zone, while the muscle tissue exhibits much lower
fluorescence in the red wavelength region. The
autofluorescence also shows a lower intensity in the tumour
tissue than in the muscle in this ex vivo scan. By comparing
the spectra in Figures and 2, it can be concluded that no
major differences exist in the shape or relation of the various
peaks and evaluation points in the spectra, whether the spec-
tra were recorded exteriorly, in vivo, or interiorly, ex vivo.
The higher fluorescence values in Figure 2b for CP(OMe)3
could perhaps be attributed to the greater build-up of the
substance CP(OMe) than of CP(Me)3 in tumour, as dis-
cussed in Reddi et al. (1994).
In several spectra, as seen in some of the graphs in Figure
2, a small peak at approximately 590nm is observed. The
same peak was also seen in the non-injected control animals.
A similar peak has been observed also in cinical fluorescence
measurements, e.g. in astrocytomas and human tonsil cancers
(Andersson-Engels et al., 1991a; Str6mblad et al., submitted).
It is probably attributable to some endogenous porphyrin,
perhaps bacterially synthesised (Harris & Werkhaven, 1987).
Another possibility is that the fluorescence is related to some
metalloporphyrin, probably zinc haematoporphyrin (ZnHp),
which is synthesised by the tumour itself (Moan, 1986; Plus,
1992). No significant difference between tumour and normal
tissue could be seen in the fluorescence intensity at this
wavelength, in the measurements carried out 3 and 24 h post
injection. This is true for both the injected and the non-
injected control animals, evaluated at corresponding times.
The intensities were in the same range for the control animals
and the animals evaluated 3 h after administration of the two
carotenoporphyrins, which all had had their tumours trans-
planted at the same time. In the measurements 48 and % h
post aministration, with much necrosis, the tumours
exhibited somewhat higher intensities at 590 nm, but with no
great significance, owing to large fluctuations in the sig-
nal.
TIhe evaluated data from all the tumour scans are shown in
Figure 3a for CP(Me) and Figure 3b for CP(OMe), with the
in vivo externally recorded scans at the top and the ex vivo
intemally measured scans below, in each figure. Each graph
represents an average of the measurements for each group of
animals, usually consisting of five mice, but in two cases
[CP(Meh and CP(OMe) at 48 hM only of four, evaluated at
3, 24, 48 or 96 h post administration. Both the exterior and
interior scans are shown in terms of the averaged
background-free substance-related fluorescence intensity, A,
expressed in units relative to a fluorescence standard and as
the ratio between A and the tissue autofluorescence B. In all
graphs, the vertical bars indicate ± I standard deviation. The
general trend for CP(Me) is that the standard deviations
increase with time after injection. This phenomenon might
partly be caused by a greater amount of necrosis in the later
measurements, which results in larger fluctuations in the
fluorescence signal.
Figure 3 clearly shows that the main fluorescence peak (A)
has a larger intensity in tumour for both substances. On
average, the intensity increase in tumour compared with
muscle is about 5 for CP(Me) and 5.6-6.8 for CP(OMe).
An important property of both substances is the tumour
selectivity demonstrated in the scans with the registration
2 mm outside the tumour, in muscle, where the intensity is
approximately equal to the point 5 mm outside the tumour,
i.e. no increase is seen on approaching the tumour. The
fluorescence intensity is not elevated until the tumour is
reached. Except in the case of the data 48 and 96 h post
injection with CP(Me), the standard deviations are small.
The intensity of the carotenoporphyrin-related fluorescence
(A) increases over time up to 48 h for CP(Me) and then
starts falling off, probably reflecting an initial build-up of the
substance in the tissues and then a consecutive claring. In
the case of CP(OMe)3, A decreases slightly when going from
3 h to 24 h post injection, then it remains relatively constant
up to 48 h and, finally, falls off during the following 48 h.
(Note the change in scales with increasing times.) This is
probably because the substance is cleared from the tissues.
The tumour/muscle ratio, in terms of the free-standing peak
A is, for CP(Me)3, 5.5 at 3 h, 5.9 at 24 h, 7.5 at 48 h and 3.4
at 96 h. The corresponding ratio for CP(OMe) is 3.8, 5.4, 9.1
and 8.4. In the case of CP(Me), the tumour/muscle ratio
remains relatively constant over time, since the fluorescence
intensities decrease in the same proportions in muscle and in
tumour. For CP(OMe)3, the tumour/muscle ratio increases at
48 and 96 h post administration, indicating that the sub-
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If the endogenous fluorescence is included, forming the
ratio A/B, the tumour/muscle ratio is enhanced to 7.3 at 3 h,
9.5 at 24 h, 12.5 at 48 h and 7.9 at %h, and 8.2 at 3 h, 9.3 at
24 h, 10.3 at 48 h and 11.2 at 96h for CP(Me) and
CP(OMe)3 respectively. The increase in the tumour/muscle
ratio varies between 27% and 400%, with an average of
about 95%, when the autofluorescence is included. The ex-
tremely high values of several hundred per cent contrast
enhancement probably are due to a reduction in the
autofluorescence because of necrosis, as pointed out
previously, which also means that the contrast is enhanced at
the expense of a greater uncertainty in the results (see, for
b
Figwe 2 Laser-induced fluorescence spctra recorded ex vivo 3 h post i.v. injection with a, 5.0mgkg-' b.w. CP(Me)3 and b,
5.2 mg kg-' b.w. CP(OMe)3. The spectra were recorded in 20-mm-long scans in peritumoral and tumoral tissue in the tumour leg
and as a single point in healthy muscle in the other klg. The measurements were carried out with the fibre probe interstitially
located in the tissues. The fluorescence intensity is expressed in relative units. Note that the scales are different in the two
scans.
ohLOCALISATION OF CAROTENOPORPHYRINS USING LIF 877
example Figure 3a, % h post injection in vivo). The main The results from Figure 3 are summarised in Figure 4. The
advantage of forming the ratio is that it is dimensionless, tumour/peritumoral muscle ratio is plotted for the two
which means that the results are rather insensitive to fluctua- carotenoporphyrins as a function of time after administra-
tions in the excitation source and the detection equipment, as tion. Figure 4a shows the tumour/muscle ratio using the
well as to topographic and distance differences in the substance-related peak., A, as an average ofall the in vivo and
measurement procedure. ex vivo measurements, whereas Figure 4b shows the same for
a
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Fge 3 Averages of the fluorescence intensity at the main peak 'A' (relative units) and the fluorescence ratio (A/B) in healthy
muscle and tumour tissue in the different groups, as measured at 3, 24, 48 and % h post i.v. injection with a, 5.0mg kg-' b.w.
CP(Me)3 and b, 5.2mg kg-' b.w. CP(OMe)3. (Note the change in scales with increasing times.) Five animals were analysed in each
group, except for the two batches at 48 h, consisting of four animals each.373 H. NlSSON et at.
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Fge 4 Tumour demarcation (tumour/musce ratio) at 3, 24, 48 and 96 h post i.v. injection with 42 gmol kg-' of CP(Me)3 or
CP(OMe). Each graph displays the extnior (D) and inteior (A) measuranent series. The tumour/muscle ratio was llated
using a, the background-free bse R en intensity 'A' and b, the ratio of the fluorescence intensity 'A' and the
enognus fluorescence 'B'.
the ratio A/B. From Figure 3 and 4a it can be concluded that
CP(OMe) is ckared faster from muscle tissue than from
tumour tissue, as compared with CP(Me)3. When the native
fluorescence is taken into account, the in vio (exterior) and
ex vivo (interior) measurements differ in demarcation power
(i.e. tumour/muscle ratio) for both substances, mainly
reflecng a law uncertainty in B. As already mentioned, the
excitation wavelength used at 425 nm is not optimal for
exciting the native fluorescence owing to the strong
interference of blood absorption, which especially affects the
interior measurements. Thus, the average of the interior
demarcations is about 25-31% lower than the exterior
ones.
In order to assess the actual consistency and relability in
the demarcation between diseased and healthy tissue, a dis-
crimination function (D) was defined as follows (Andersson-
Engels et al., 1991a):
Average... - Average,,
J(a_2 + **L)
where the averages denote the mean values of the fluor-
escence intensities at the various times after injection of the
two carotenoporphyrins and at the different measurement
locations (inside or outside the tumour regions). The value of
a denotes one standard deviation. This function is a paralel
to the 'z-test', which means that it is a measure of how far
apart the error bars of the two compared functions (in this
case fluorescence intensity inside and outside tumour) are
separated. In other words, the larger the Dk value is, the
more certain the demarcation. For these measurements, the
number of points considered in each group and site (exterior
or interior scan) was approximately 25-40.
alculating the number of degrees of freedom (number of
points-2) and as ing a signiie level of 5% (P<0.05),
it can be found in tables that if (Di> 1.7, the demarcation is
significant to the aforementioned level. For the ratio A/B,
this criterion was fulfilled for both the substances at 3 and
24 h post injection, whereas only CP(OMe) fully passed the
test for the later scans. Probably because of problems with
the tumour model used, as previously expained, CP(Me)3 did
not show a sufficient Dk in the later, exterior scans. For most
groups, the values were exceeding 3, which indicates that the
discrimination is excellent. When creating the diination
coefficint for the peak A alone, about the same trend as for
the ratio is followed, but, generally. with smaler values.
In conchlon, CP(Me)3 and CP(OMe)3 are shown to
demarcate malignant tissue from normal, surrounding tissue
at ratios of about 5:1 and 6:1, rpiy, in the tumour
model used. If the tissue autofluorescence is inluded, the
dmarcation is enhancd to 8-10:1 and 9-12:1, iespectively,
with a higher emarcation in the exterior scans. The
carotenoporphyrins are quickly taken up by the kind of
tumour used, and already show a good and consistent de-
marcation 3 h after administration, which is a good indica-
tion for possible future clinical use. CP(Me) exhibited
smaller standard deviations 3 h post injection; thus, this sub-
stance might be the one of choice in a cinical situation.
However, at the injected doses, CP(OMe) exhibits a more
intense fluorescence at the main peak, A, than CP(Me),
which might indicate the possibility of a dose reduction in
the former case. This could be of vae in a clinical situation,
because of the inhmeent substance characteristic of
accumulating in the riculoendothelial system, as descnrbed
by Reddi et al. (1994).
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